Skip to main content

Regulatory & Access Resources

Browse our regulatory & access resources to find the latest articles, blogs, brochures, and videos from our experts. See the latest content below.

Nothing Costs More Than Failure: The Benefits of Early Commercial Strategy Development

Learn more about Market Access Planning here!

Download PDF

Early commercial strategy during drug development is a critical element of market access planning. If your payer deems the drug ‘benefit not proven’ you could be forced to run more studies or abandon the trial altogether.

The top reasons drugs fail to be recommended for market access are: 

1. Non-robust economics 

2. Uncertain clinical benefit 

3. Inappropriate trial design, comparator, or patient population 

4. Increased drug costs 

5. Safety concerns 

All of these reasons signify the importance of evidenced-based strategy early in the development process and a development partner that keeps market access and reimbursement requirements front of mind.